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Current and Emerging Imaging Techniques in the Diagnosis and Assessment of Pulmonary 
Hypertension 
 
  
Abstract 
 
Introduction 
Pulmonary hypertension (PH) is a challenging condition to diagnose and treat. There have been many advances in therapies over the last 2 decades,, along with a rapid 
development of imaging technologies. The increasing availability of non-invasive imaging gives physicians an unrivalled opportunity to improve diagnostic rates and 
accurately phenotype patients.  
 
Areas covered 
This review discusses the role of imaging in the diagnosis, prognostic assessment and follow-up of patients with PH. Imaging methods, ranging from readily available 
investigations (chest radiography, echocardiography, nuclear medicine and cross-sectional C (CT), to emerging modalities (magnetic resonance imaging (MRI) and positron 
emission tomography (PET)) are reviewed. The value and limitations of these clinical application of these imaging modalities and their the evidence for  clinicalapplication 
isreviewed. 
 
Expert commentary 
Imaging plays a key role in the diagnosis and classification of pulmonary hypertension. It provides valuable prognostic information and increasingly evidence supports serial 
assessments. The authors anticipate an increasing role for imaging in the pulmonary hypertension clinic.  This will reduce the need for invasive investigations, in addition to 
providing valuable insights that will improve our understanding of disease and allow more targeted approaches to treatment. 
 
 
  
Introduction 
 
Pulmonary hypertension (PH) LVGHILQHGDWULJKWKHDUWFDWKHWHULVDWLRQDVDPHDQSXOPRQDU\DUWHULDOSUHVVXUHP3$3PP+J[1]. It ranges from often mild elevations of 
pulmonary artery pressure, frequently seen in the context of cardiac and respiratory disease, to severe elevations of pressure in patients with an underlying pulmonary arterial 
vasculopathy [2]. Regardless of its aetiology, it has a negative impact on both symptoms and survival. The current classification identifies 5 groups with similar clinical and 
pathological characteristics; Group 1: Pulmonary arterial hypertension (PAH), Group 2: Pulmonary hypertension due to left heart disease (PH-LHD), Group 3: Pulmonary 
hypertension due to lung disease and/or hypoxia (PH-lung),Group 4: Chronic thrombo-embolic pulmonary hypertension (CTEPH), and Group 5: Pulmonary hypertension with 
unclear/multifactorial mechanisms [3]. Key aspects of the management of pulmonary hypertension include establishing the diagnosis of pulmonary hypertension, identifying 
the form of pulmonary hypertension (which defines the optimal treatment strategy) and the follow-up of patients.  
The diagnosis of pulmonary hypertension is usually suggested by an echocardiogram performed in the breathless patient [2], although increasingly the diagnosis is suggested 
following other imaging investigations, in particular computerised tomography (CT) [3]. Once a diagnosis of pulmonary hypertension is suspected it is important to identify the 
cause as this defines the optimal treatment strategy [3]. Conditions for which therapies directed at the pulmonary vasculature have been proven to be effective are uncommon 
(such as PAH and CTEPH). Other forms of pulmonary hypertension, such as PH-LHD and PH-Lung disease, are much more common, but currently for these forms of 
pulmonary hypertension, treatment is aimed at the underlying disease not the pulmonary vasculature. Diagnostic strategies including confirming the diagnosis of pulmonary 
hypertension with cardiac catheterisation and the approach to imaging is therefore dependent on the physician ensuring that further investigation is in the best interests of 
the patient. An important part of this strategy is an appreciation of factors that increase the pre-test probability of identifying forms of PH likely to benefit from therapy. 
Features from the history are important; a previous history of thromboembolic disease raises the probability of CTEPH. Alternatively, features known to increase the likelihood 
of PAH such as the presence of an underlying connective tissue disease (e.g. systemic sclerosis, with a prevalence of PAH 9% [4]), portal hypertension (prevalence of PAH 2-6% 
[4]), HIV (prevalence of PAH 0.5% [4]) should also be sought. In contrast, mild elevation of pulmonary artery pressures, in the context of severe respiratory or cardiac disease, 
may not require further investigation where there are no red flag features such as, severe elevation of pulmonary artery pressures or severe impairment of right ventricular 
function.   
Imaging plays an important role in the diagnosis and classification of pulmonary hypertension and provides prognostic information. This review describes a number of 
imaging methodologies that can be implemented in the assessment of suspected pulmonary hypertension.  
1 Imaging the cardiopulmonary circulation 
 
1 Chest Radiograph 
The chest radiograph is well established as a first line imaging technique for assessment of patients with known or suspected lung disease, providing a general overview of 
the lungs and pulmonary vasculature. It is helpful in providing a guide to further investigation in patients with unexplained breathlessness, but is insensitive for the 
detection of pulmonary hypertension, particularly, where pulmonary artery pressure elevation is modest.  It provides limited information on potential causes of pulmonary 
hypertension, but may identify the presence of significant lung disease such as emphysema, pulmonary fibrosis or characteristic changes of sarcoidosis. It is has the 
advantage that is widely available, utilises minimal doses of radiation and is easily interpreted by medical practitioners. Typical findings in pulmonary hypertension include 
dilatation of the pulmonary arteries, right atrial and right ventricular enlargement, although the later are features of severe disease. In a historical study of patients with 
Idiopathic PAH, an abnormality on CXR or electrocardiography (ECG) was found in 90% of patients [4], however, this represents a highly selected population of patients with 
severe disease and the accuracy of CXR in an unselected population of patients with suspected pulmonary hypertension has not yet been studied. 
 
2 Echocardiography 
Echocardiography is widely available and is usually the first non-invasive imaging investigation to suggest a diagnosis of pulmonary hypertension [3]. Echocardiography has 
the advantage of high temporal resolution with direct visualisation of cardiac motion, allowing assessment of right and left ventricular function and estimation of 
pulmonary artery pressure, whilst also being portable and easily performed at the bedside.  Systolic pulmonary artery pressure can be measured using Doppler 
echocardiography; The peak tricuspid regurgitant jet velocity (v), measured from Doppler echocardiography, is used to calculate the tricuspid gradient (TG) (pressure 
difference between right ventricle and right atrium) using the modified Bernoulli equation, TG=4v2 . This is then added to an estimate of right atrial pressure to estimate 
right ventricular systolic pressure, which should be equivalent to systolic pulmonary artery pressure in the absence of pulmonary valvular disease. Right atrial pressure is 
estimated as either 5, 10 or 15mmHg based on the diameter and respiratory variation of the inferior vena cava [10]. Whilst several studies have identified a strong 
correlation of echo derived sPAP and right heart catheter measured mPAP in cardiac disease [11,12] the diagnostic utility of echocardiography derived pulmonary artery 
pressure is less accurate in  pulmonary hypertension seen in the setting of respiratory disease. A prospective study of unselected patients with PH, identified the 
inaccuracies of Doppler echocardiography derived mPAP, with limits of agreement ranging from -40 to 38.8 mmHg [13]. Echocardiographic estimation of sPAP can only be 
performed in the presence of tricuspid regurgitation and where this is absent, mean pulmonary artery pressure can also be estimated using systolic time intervals such as 
pulmonary acceleration time [14,15]. 
Echocardiography also allows an assessment of cardiac valves and may identify congenital heart defects. The morphological characteristics of chronic right ventricular 
pressure overload described using echocardiography include flattening of the inter-ventricular septum (IVS), increased thickness of the right ventricular free wall and 
increased left ventricular eccentricity. In addition, tissue Doppler is helpful in the assessment of diastolic function [16]. Injections of agitated saline (bubble echo) can be 
used to look for right to left shunting and whether this occurs at an intracardiac or pulmonary level [17,18]. Transoesophageal echocardiography is particularly helpful in the 
assessment of suspected intracardiac defects such as atrial septal defects which are often not well visualised on transthoracic echocardiography [19].  
 
3 Radionuclide Imaging 
Ventilation/perfusion single photon emission tomography (V/Q SPECT) is currently recommended by the European Society of Cardiology (ESC) as the first line screening test 
for chronic thromboembolic pulmonary hypertension (CTEPH) [18]. The perfusion image entails injection of 100MBq of 99mTc labelled macroaggregated human albumin, 
exposing the patient to ionising radiation with an effective dose of approximately 0.017mSv/MBq [20]. The macro-aggregated albumin is trapped within the small 
pulmonary arterioles, and a 3D reconstructed image of the perfusion of the lungs is acquired over around 10 minutes. In CTEPH, characteristic wedge shaped perfusion 
defects, mismatched to ventilation can be demonstrated. The advantage of this technique over CT is that image interpretation is relatively straightforward and a normal 
scan excludes the diagnosis of CTEPH. In contrast, the absence of perfusion due to attenuated vessels and the presence of endo-luminal chronic thromboembolic disease 
may not be appreciated on CT by less experienced observers. Initial studies demonstrated that scintigraphy was significantly more sensitive than CT although more recent 
studies have demonstrated that in expert hands that CT and 3D MR perfusion techniques are equally sensitive when compared with scintigraphy [21 W23]. In addition, 
imaging of systemic vascular beds (kidneys or brain) can be used to quantify the size of a right to left shunt and can be considered in a patient with unexplained hypoxaemia 
and pulmonary hypertension [19]. 
 
4 Computed Tomography Pulmonary Angiography (CTPA) 
Computed Tomography (CT) is the main imaging modality for the assessment of pulmonary parenchymal abnormalities and the most recent guidelines [3] suggest that this 
investigation should be considered, particularly if there are abnormalities of gas transfer identified on lung function testing. In suspected pulmonary hypertension, a CT 
pulmonary angiogram (CTPA) is increasingly performed: a bolus of iodinated contrast is administered typically into the antecubital vein and the scan is acquired ideally at 
the point of optimal opacification of the pulmonary arteries. CTPA provides information on the pulmonary vasculature and the size of cardiac chambers, and aids 
identification of the form of pulmonary hypertension. In patients with PAH there are characteristic CT findings, which reflect the severity of pulmonary hypertension [23]. In 
a large cohort of patients with pulmonary arterial hypertension a systematic assessment of vascular, cardiac, parenchymal and mediastinal features demonstrated 
characteristic features of various forms  of pulmonary arterial hypertension and also identified important prognostic markers [31]. 
A well-established feature of pulmonary hypertension is an increased diameter of the pulmonary artery (PA).  A number of thresholds have been used to identify the 
presence or absence of pulmonary hypertension. In one study, a transverse PA diameter of >29 mm on CT was shown to have a high positive predictive value (97%) for PH 
[32] whereas another study used a value of 33 mm [33], and a pulmonary artery with a larger diameter than the adjacent ascending aorta (pulmonary artery-aorta ratio >1) 
has also been shown to be predictive of PH [32]. In patients where there is a high prevalence of pulmonary hypertension, such as systemic sclerosis, interrogation of the CT 
can be helpful where an enlarged PA may be the first indicator of the presence of pulmonary hypertension. Dilatation of the PA in this setting, in particular a pulmonary to 
aortic ratio of >1.0, can be highly predictive [34,35].  CTPA is particularly useful in CTEPH, where the distribution of vascular webs, stenosis and mural thrombus allows for 
treatment planning and assessment of suitability for pulmonary endarterectomy. Serpiginous vessels within the pulmonary parenchyma are seen in severe pulmonary 
hypeƌƚĞŶƐŝŽŶ ?ƉĂƌƚŝĐƵůĂƌůǇŝƐĞŶŵĞŶŐĞƌ ?ƐƐǇŶĚƌŽŵĞ but may also be seen in idiopathic PAH, and are likely  to represent neovascularity [28].  
Pulmonary hypertension causes remodelling and eventual failure of the right ventricle. Whilst this is visible on CTPA, it is rarely seen in the early stages of disease. CTPA 
evidence of right ventricular compromise includes dilatation of the right heart chambers, right ventricular hypertrophy (defined as wall thickness of more than 4 mm) and 
bulging of the interventricular septum towards the left ventricle [40]. Changes of right ventricular hypertrophy are often best appreciated in the right ventricular outflow 
tract, likely reflecting the reduced quantity of trabeculation. Reflux of contrast into the inferior vena cava and hepatic veins on contrast enhanced CT has been considered 
to be a marker of the severity of tricuspid regurgitation, commonly seen in pulmonary hypertension [41], often in PH-LHD, although in the authors experience, it correlates 
poorly with the severity of pulmonary hypertension. In severe pre-capillary pulmonary hypertension such as PAH, CTEPH and PH associated with respiratory disease (where 
there is severe pulmonary hypertension) the left ventricle is under filled and compressed by the dilated RV, causing a small volume left atrium and ventricle. There may also 
be features of cardiac decompensation also visible on CT, such as pleural and pericardial effusions, and an increase in inferior vena caval size, all of which are associated 
with a  poor prognosis [31].  
Pulmonary parenchymal changes may help to identify the cause of pulmonary hypertension. In patients with pulmonary hypertension due to lung disease, CT can identify 
the underlying lung disease and monitor changes in severity. Patients with IPAH often have centrilobular ground glass opacities [42] (as shown in figure 2), which have also 
been described in patients with pulmonary veno-occlusive disease, where additional characteristic features may also be present such as septal lines and lymphadenopathy 
[43]. Patients with CTEPH often have regions of sub-pleural scarring from infarction and a mosaic pattern of lung attenuation due to perfusion heterogeneity.  Although not 
in routine clinical use, more specialised methodologies in CT such as ECG gating [44] and dual energy CT for perfusion imaging have been implemented as research tools in 
pulmonary hypertension [45 W47]. 
 
5 Magnetic Resonance Imaging 
MRI is considered the gold standard for functional and morphological assessment of the heart. Standard sequences implemented in pulmonary hypertension include two 
and four chamber cardiac cine steady state free precession imaging (SSFP), black blood imaging (dual inversion recovery fast spin echo), contrast enhanced MR angiography 
and 3D dynamic contrast enhanced MR imaging. Cardiac MRI can be used to diagnose pulmonary hypertension [55,56], assess prognosis and increasingly its utility in follow-
up of patients is being assessed. 
 
Cardiac Cine MR Imaging 
Retrospectively ECG gated cardiac cine imaging in the two and four chamber views allow for qualitative and quantitative assessment of the structure and function of the 
ventricles [57]. Segmentation of the ventricular endocardium quantifies the right and left ventricular end-diastolic and end-systolic volumes from which stroke volume and 
ejection fraction can be calculated. Baseline RV end-diastolic volume and RV ejection fraction and the change in RV ejection fraction over time are both predictive of 
outcome [58,59]. RV stroke volume measured using cine imaging is less reproducible due to inaccuracies in contouring the ventricles, although new software allowing for 
thresholding of trabeculation may improve reproducibility. In addition, due to the variable nature of tricuspid regurgitation, RV stroke volume measured by volumetry is a 
poor reflector of forward pulmonary arterial flow . 
The myocardium of the left and right ventricles can be segmented, giving right and left ventricular mass. The ratio of these is the ventricular mass index (VMI = RV mass / LV 
mass), which correlates with mean pulmonary arterial pressure in patients with pulmonary hypertension [62].  
In health, left ventricular pressure is significantly greater than the right ventricular pressure, giving a characteristic circular shape to the left ventricle, and a 
crescentic shape to the right ventricle on short axis views. The angle of the inter-ventricular septum can be measured, it is increased (deviating towards the LV) 
in patients with pulmonary hypertension [63]. This has been shown to correlate with pulmonary artery pressure although in the presence of left heart disease 
septal angle measurements are less accurate due to the confounding effect of elevated left ventricular diastolic pressures. 
 
Functional Imaging of the Pulmonary Artery 
Black blood imaging is used to provide a morphological assessment of the pulmonary arteries and aorta. In health, there is high contrast between the flowing blood in the 
pulmonary arteries (black) and the pulmonary artery wall (high signal/white). A reduction in blood velocity and turbulent flow results in high signal within the pulmonary 
arteries, a strongly diagnostic and prognostic feature of PH, described as black blood flow artefact.  
Phase contrast MRI is a technique that allows for quantification of blood flow. Pulmonary arterial flow, velocity and area change can be calculated and have been shown to 
have clinical value in the assessment of patients with PH.   
Detailed analysis of flow can be obtained using 4D phase contrast flow imaging, in which time resolved 3D datasets of flow are acquired. This can be 
retrospectively interrogated to analyse flow in multiple regions of interest in the heart or pulmonary vasculature. In pulmonary hypertension, vortices can be 
seen within the pulmonary artery [64], and the duration of these vortices have been shown to be predictive of the presence of PH [65,66]. Further research 
examining the clinical utility of 4D flow MRI is warranted.  
 
Contrast Enhanced Angiography and Perfusion Imaging 
High spatial resolution 3D images of the pulmonary arteries (contrast enhanced MR Angiogram) can be acquired with the injection of intravenous T1 shortening agents. 
Typically, a bolus of gadolinium is administered into a large proximal vein (normally in the antecubital fossa) followed by acquisition of a T1 weighted 3D gradient echo 
dataset, after a delay that has been assessed by a test bolus. This produces high resolution images of the pulmonary vasculature, with good arterial and venous separation, 
which can be useful in the identification of proximal thrombus [67].  
Time resolved Imaging of contrast provides high-resolution angiographic assessment of the pulmonary circulation haemodynamics. These are also particularly useful to 
assess for right-to-left shunts. Using a lower spatial, but higher resolution acquisition, the dynamic passage of contrast through the pulmonary parenchyma can also be 
imaged, with a frame rate of around 0.5s. This data is often presented as the peak signal for each voxel ?ĂĨƚĞƌƚŚĞŽƌŝŐŝŶĂů ‘ƵŶĞŶŚĂŶĐĞĚ ?ĚĂƚĂƐĞƚŚĂƐďĞĞŶƐƵďƚƌĂĐƚĞĚ ?ŐŝǀŝŶŐ
a peak perfusion image [22]. This is particularly useful in the assessment of CTEPH and has been shown to be of equivalent sensitivity to perfusion SPECT imaging [21]. 
Dynamic contrast enhanced MRI can also be quantified [68 W71], potentially allowing for easier longitudinal follow up of perfusion abnormalities in pulmonary hypertension 
[60] 
 
Magnetic resonance imaging tissue characterisation 
Late gadolinium imaging is in common usage in the assessment of patients with myocardial infarction, to assess for myocardial scar tissue [72]. The technique utilizes a T1-
weighted inversion recovery sequence performed 10 to 15 minutes after injection of gadolinium (a T1 shortening agent). Normal myocytes enhance early, but wash-out as 
they do not trap gadolinium, whereas abnormal tissues, such as fibrosis, trap the gadolinium and remain enhanced on delayed imaging [72]. In patients with pulmonary 
hypertension, late gadolinium enhancement is seen in the right ventricular insertion points and in the interventricular septum [73], it is thought that these areas are 
exposed to mechanical stress. The extent of right ventricular insertion point and interventricular septal late gadolinium enhancement has been shown to correlate with 
right ventricular function [74].  
A similar pattern of disease can be seen on native T1 mapping (i.e. non contrast enhanced T1 values), with high native T1 values in the RV insertion points [75], which 
correlates with right ventricular dysfunction [76]. This allows the potential to characterise myocardial tissue, without the use of contrast media and potentially providing a 
method for the identification of patients at risk of adverse right ventricular remodelling and right ventricular failure.  
6 Digital Subtraction Pulmonary Angiography 
Digital subtraction angiography (DSA) of the pulmonary artery is an invasive test, in which iodinated contrast is administered through a catheter in the pulmonary artery 
under fluoroscopic visualisation. DSA is used in many centres in patients with chronic thromboembolic disease to guide surgical intervention [77] and is currently 
recommended in the ESC guidelines as a final step in the surgical assessment of CTEPH. The advent of CTPA and MR angiographic techniques provide an alternative non-
invasive approach to assess suitability for pulmonary endarterectomy. More recently, the authors have demonstrated that in a large population of patients with suspected 
CTEPH that a first line imaging approach using nuclear medicine imaging, CTPA, 3D perfusion MR and MR angiography can be successfully used to identify patients with 
CTEPH for pulmonary endarterectomy with a low peri-operative mortality [82]. 
 
7  Positron Emission Tomography 
Fluorodeoxyglucose (FDG) is a glucose analogue, which is typically bound to 18-Fluorine, a positron emitter. 3D images of the uptake of FDG can be produced using a PET 
scanner (positron emission tomography), which allows for qualitative and quantitative assessment of tissue glucose uptake and therefore, an assessment of metabolic 
activity. As the spatial resolution of PET scanning is relatively low, the scan is performed at the same time as CT, for anatomical location. In IPAH, there is significantly 
increased FDG uptake within the right ventricle and heterogenous uptake within the lung parenchyma [74 W76]. In a few centres the availability of PET-MRI scanners allows 
anatomical location of the uptake on cardiac MRI [86], providing clearer anatomical detail and functional information.  
 
  
Clinical applications of imaging in pulmonary hypertension 
 
Making the diagnosis of pulmonary hypertension 
There are many causes of pulmonary hypertension. The identification of the cause is key in defining treatment: patients with PAH benefit from drug therapy, whilst patients 
with CTEPH can be potentially cured by pulmonary endarterectomy. The diagnosis may be suggested incidentally by an imaging investigation performed for unexplained 
breathlessness, such as large central pulmonary arteries on chest radiograph or CT. The diagnostic approach for patients was highlighted in recent ERS/ESC guideline [3], 
however, the approach is dependent in part on local availability of imaging and expertise.  
In the authors͛ own institution, which is a tertiary PH referral centre for pulmonary hypertension, a multimodality approach is used 
combining radionuclide imaging, CT, MRI and cardiac catheterisation. As many patients travel long distances for their investigations, a 
single step approach is taken to reduce the requirement for repeat visits. In other centres, a step-wise approach may negate the need 
for some of the diagnostic tests. 
Prognostic evaluation of patients with pulmonary hypertension 
The assessment of prognosis is important in planning treatment, in particular when considering interventions such as initiation of parenteral prostanoid therapy and 
triggering referral for transplantation.  Accurate assessment of prognosis allows for adequate counselling of patients. This assessment is usually based on an assessment of 
clinical status, exercise capacity and right ventricular function. A wealth of prognostic information can be gained from the clinical status of the patient, and World Health 
Organisation (WHO) functional class is a useful tool in this regard. A historical study showed that patients with WHO functional class IV had median survival of 6 months, 
class III had a median survival of 2.5 years and class I and II had a median survival of 6 years [89]. Older age, male sex and poor exercise capacity are associated with a worse 
prognosis and the cause of pulmonary hypertension also impacts on outcome [90 W95]. Right ventricular function may be measured in different ways. Serum levels of NT-
proBNP are linked to right ventricular dysfunction, and have been shown to have prognostic value in PAH [94]. On echocardiography, right ventricular function and disease 
severity can be assessed using tricuspid annular plane systolic excursion (TAPSE) [96], the RV Doppler index [97,98], interventricular septal displacement [99] and with the 
right atrial area index [99], all of which predict outcome. At right heart catheterisation, a number of measurements can be used to assess prognosis including right atrial 
pressure, cardiac output/index, stroke volume index and mixed venous oxygen saturation.  
Cardiac MRI is also a useful tool in the assessment of prognosis. Multiple studies have identified that stroke volume, RVEF, LV and RV end diastolic volumes are associated 
with outcome [101,102], particularly when adjusted for age and sex [103]. The strength of RVEF as a predictor of outcome in PAH was highlighted in a recently published 
systematic review [104]. More recently, a larger study of 576 patients from our centre showed that right ventricular end systolic volume (indexed for age and sex) and 
pulmonary arterial relative area change were independent predictors of mortality, providing added prognostic value to patient age, sex, subgroup diagnosis and WHO 
functional class [55]. The presence of a pericardial effusion on echocardiography, CT or cardiac MRI is also associated with a poor prognosis [99], and other features of 
cardiac decompensation such as pleural effusions and ascites are predictive of a poor outcome.   
The challenge facing clinicians is how to incorporate large amounts of data from various imaging modalities and how best to integrate these with other data from the clinic 
to aid treatment decisions in a way that is meaningful and beneficial to patients. 
 
Follow-up of patients with pulmonary hypertension 
A number of parameters are used to assess patients progress including WHO functional class [94], exercise testing measured using field walking tests such as the 6MWT 
[105,106] and incremental shuttle walking test [107] and widely available blood test such as N-terminal BNP [108,109]. There has been some concern regarding the ability 
of the 6MWT to reflect changes in pulmonary vascular status and this has led to a drive to explore other markers that are more likely to be sensitive to change. 
Consequently, there has been a lot of recent interest in cardiac MRI as a highly reproducible, non-invasive, non-ionising tool to assess right ventricular function. Van de 
Veerdonk and colleagues, showed that cardiac MRI is sensitive to change, with right ventricular volume changes preceding clinical deterioration in apparently clinically 
stable patients with idiopathic pulmonary arterial hypertension [110]. The same group also showed that changes in stroke volume were a marker of clinical improvement in 
patients after 1 year of treatment [111]. Further to this, measures of right ventricular function on cardiac MRI have been shown to be highly reproducible [55]. 
In our centre, we use a multi-modality approach to follow up based on clinical assessment, exercise testing and cardiac MRI to assess response to treatment. Cardiac MRI is 
not readily available in all centres, so the choice of follow up modality is also based on real life local availability of tests. Echocardiography is an alternative for follow up, 
able to objectively quantify right ventricular function using TAPSE, right ventricular tissue Doppler and right ventricular free wall strain, although there are concerns 
regarding the reproducibility of this technique and how it performs as a follow-up tool in routine clinical practice [112 W114]. Recently a study has shown that using a simple 
assessment of symptoms (WHO FC), exercise capacity (6 minute walk test distance) and BNP at follow-up, could be used to risk stratify patients, with no additional benefit 
provided by performing cardiac catheterisation [82]. In summary, a number of approaches are used in the follow-up of patients, however, the authors suggest that these 
should include a measurement of symptoms, exercise capacity, right ventricular function and also patient reported outcome measures such as emPHAsis-10 [115].  
 
Conclusion 
 
Imaging plays a key role in the diagnosis of pulmonary hypertension and is increasingly used in the follow-up and monitoring of patients. The last 2 decades have seen 
significant advances in imaging techniques and a move towards the use of multiple imaging modalities in the assessment of patients with pulmonary hypertension. Despite 
this, many of the recommendations on the use of imaging approaches are based on expert opinion and studies include relatively small numbers of patients. There is no 
doubt that given the heterogeneity of pulmonary hypertension that large studies and a move towards standardisation of imaging protocols and international collaboration 
is required if we are to realise the potential of imaging in pulmonary hypertension. Larger datasets allow for analysis with approaches such as machine learning not only of 
measurements derived from image analysis, but also inputting the raw images themselves [88]. Using empirical linear regression models [35], or more physiologically linked 
models [89] may also aid the diagnosis of pulmonary hypertension and refine our approaches to assessment of disease progression and combining imaging metrics with 
 “ŽŵŝĐƐ ?ŵĂǇƉĂǀĞƚŚĞǁĂǇĨŽƌƉƌĞĐŝƐŝŽŶ medicine and tailored therapy. Large multi-centre studies examining different diagnostic approaches to the investigation of 
pulmonary hypertension are lacking and there is only limited data on the cost effectiveness of different approaches to both diagnose and follow-up.  Importantly, however, 
there are a number of ambitious imaging studies on the horizon, and it is important that the pulmonary hypertension community embraces initiatives such as CHANGE-MRI, 
a multicentre study specifically examining the optimal approach to the diagnosis of CTEPH, if we are going to realise the full potential of imaging.  
  
Key Points 
1. Imaging is key in the assessment of patients with suspected pulmonary hypertension. 
2. Imaging characteristics can provide important information on the cause of pulmonary hypertension. 
3. Non-invasive methodologies such as cardiac MRI and CT can provide useful prognostic information. 
4. Cardiac MRI is sensitive to change and reproducible, making it ideal for follow up. 
5. Large studies are required to assess the role of non-invasive imaging modalities. 
Figures 
Figure 1: A series of images from a patient with chronic thrombo-embolic pulmonary hypertension (CTEPH). The top row shows a series of images from a CTPA showing 
mural thrombus (A and C), a dilated, hypertrophied right ventricle (B) and mosaic pattern of perfusion (D). The bottom row shows a selection of images from the cardiac 
MRI study with slow flow artefact on black blood imaging (E), dilated, hypertrophied right ventricle on short axis cine images (G), attenuation of vessels on the contrast 
enhanced MRA (G) and multiple segmental perfusion defects on the perfusion MRI (H).  
   
Figure 2: Selected image from a patient with idiopathic pulmonary arterial hypertension showing centrilobular ground glass opacities. 
 
  
Figure 3: A chest radiograph from a patient with pulmonary hypertension due to left heart disease with combined pre and post capillary disease (A) showing moderate 
cardiomegaly and upper lobe venous distension. The subsequent MRI shows bi-atrial dilatation (B), flattening of the interventricular septum (C) and slow flow black blood 
artefact (D). The flattening of the interventricular septum suggests that there is a pre-capillary component to the pulmonary hypertension.  
 
 
 
  
Figure 4: Selected images from a patient with PH due to a patent foramen ovale. The top row (A) shows the images from the time resolved TRICKs, with increasing time to 
the right of the image. On the early images, there is contrast within the aorta at a time point before filling of the pulmonary arteries, in keeping with a right to left shunt. 
This was confirmed with quantitative perfusion SPECT over the kidneys (D), which shows uptake of tracer in the capillary bed of both kidneys. The black blood imaging (B) 
shows dilated pulmonary arteries with slow flow/turbulent blood artefact and the 2 chamber image (C) shows significant flattening of the interventricular septum. 
  
Figure 5: Images from a patient with IPAH. The chest radiograph shows cardiomegaly with dilatation of the pulmonary artery, the patient has a PICC for intravenous delivery 
of iloprost. Black blood imaging (B) and CTPA (D) confirm the dilated pulmonary artery. Further features of pulmonary hypertension are shown with slow flow artefact on 
black blood (B), flattening of the interventricular septum (C) and dilatation of the right sided chambers (C and D). Note is also made of poor filling of the left sided chambers 
and a moderate pericardial effusion. 
 
 
 
 
 
  
Figure 6: Investigation flow chart in our institution. 
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 K PA“ ?A?ŽƌA?A? K PA“ŽƌA? K PA“ŽƌA? K PA“ ?A?ŽƌA?A? K PA“ ?A?ŽƌA?A? 
  Z PA“ŽƌA? Z PA?ŽƌA?A? Z PA“ŽƌA? Z PA“ŽƌA? Z PA“ ?A?ŽƌA?A? 
CT W PA?ŽƌA?A? W PA“ŽƌA? W PA?ŽƌA?A? W PA?ŽƌA?A? W PA?ŽƌA?A? 
 Zs PA?ŽƌA?A? Zs PA“ŽƌA? Zs PA?ŽƌA?A? Zs PA?ŽƌA?A? Zs PA?ŽƌA?A? 
 >sĂŶĚ> PA?A? > PA?A?    
 
Flattened IVS  Parenchymal lung disease Chronic emboli: webs, CT evidence of disease  
 Centrilobular nodules  Pleural or pericardial effusions      eg. Emphysema or fibrosis  stenoses, mural thrombus              eg sarcoidosis 
 Neovascularity   Mosaic perfusion  
CMRI W PA?ŽƌA?A? W PA“ŽƌA? W PA?ŽƌA?A? W PA?ŽƌA?A? W PA?ŽƌA?A? 
 Zs PA?ŽƌA?A? Zs PA“ŽƌA? Zs PA?ŽƌA?A? Zs PA?ŽƌA?A? Zs PA?ŽƌA?A? 
 >sĂŶĚ> PA?A? >s PA“ŽƌA? ?> PA?A?    
 
Flattened IVS Septum only flattened in Cpc-PH Flattened IVS  
  
Pleural/Pericardial Effusions   Chronic emboli on MRA   
V/Q 
SPECT No segmental defects            No segmental defects            No segmental defects            Segmental perfusion defects No segmental defects            
  Renal uptake in R-L shunt   
Abnormal due to lung 
disease     
, IVS: Interventricular septal angle
Table 2: Diagnostic accuracy for cardiac MRI metrics to predict the presence of PH. 
Author Year Cases  
(PH/not PH) 
RHC 
metric 
CMR marker Correlation (R) Threshold AUC 
Roeleveld 
[118] 
2005 44/0  mPAP VMI 0.56* N/A N/A 
Sanz [119] 2007 42/17 mPAP Average velocity -0.73** 11.7cm/s 0.90 
Diastolic PA area 0.67** 6.6cm2 
 
0.95 
PVRI Average velocity -0.86** 11.7cm/s 0.92 
Diastolic area 0.64** 6.0cm2 0.93 
Gan [120] 2007 70/16  
 
mPAP PA RAC 0.47* N/A N/A 
Garcia-
Alvarez 
[121] 
2011 100/0 
(80 derivation 
20 validation) 
PVR MR estimated 
PVR  
 
0.84** :8 0.97 
Swift [122] 2012 194/39 
 
mPAP 
 
 
VMI 0.78** >0.4 0.91 
LGE 
present/absent 
N/A LGE Present 0.89 
Diastolic PA area 0.35* >6cm2 0.84 
Moral 
[123]  
2012 152/33 mPAP Į  0.61** 7.2 0.97 
Swift [56] 
 
2013 64+64/12+10  mPAP Model CMR 
mPAP 
0.82** PP+J 0.96 
PVR Model CMR 
PVR  
0.87** :8 0.94 
Johns 
[124] 
2017 87/15 
All COPD 
patients had 
COPD 
mPAP CMR-RV model 0.689** 32mmHg 0.91 
PA/RV model 0.732** 25mmHg 0.93 
Į 0.527** 7.2 0.84 
Zhang 
[125] 
2017 50/0 
All PAH 
(25 derivation 
and validation) 
mPAP CMR mPAP Model 0.647** N/A N/A 
PVR CMR PVR model 0.492** N/A N/A 
mPAP: mean pulmonary arterial pressure, VMI: ventricular mass index, PVR(I): pulmonary vascular resistance 
(index), PA: pulmonary artery PA RAC: Pulmonary arterial relative area change, LGE: late gadolinium enhancement, * 
p <0.05, ** p <0.001 
  
Table 3:  
Author Number of 
patients 
Follow up CMR 
metric 
Hazard 
Ratio (confidence interval)  
 
Van de 
Veerdonk [126]  
 
110 PAH 1 year Baseline 
RVEF  
0.938 (0.902±0.975)** 
2QH\HDUƩ59() 0.929 (0.875±0.985)* 
RVESVI (ml/m2) 
 
1.014 (1.001-1.027)* 
LVEDVI (ml/m2) 0.962 (0.931±0.994)** 
LVESVI (ml/m2) 0.942 (0.888-0.998)* 
Van Wolferen 
[127] 
 
64 IPAH 1 year SVI (Phase contrast at 
pulmonary artery) (ml/m2) 
0.32 (0.13-0.84)* 
LVEDVI (ml/m2) 0.31 (0.13-0.81)* 
RVEDVI (ml/m2) 4.2 (1.31-8.30).* 
Gan [120] 70 4 years RAC (%) right main PA 0.87(0.76-0.96)** 
Swift [128] 134 20 months RAC (%) main PA 0.85 (0.74-0.98)* 
Hagger [129] 40 PAH-SSc  VMI N/A ± Kaplan Meier analysis 
Rajaram [130]   RVEDV 
 
1.02 (1.01-1.03)** 
 
VMI 5.56 (1.50-35.5)* 
Freed [131] 
 
58 10 months RVIP-LGE 10.0 (1.3 to 77.1)* 
Swift [132] 79 2 years FWHM 
 
1.08 (1.01 to 1.16)* 
 
PTT 
 
1.10 (1.03 to 1.18)* 
Dawes [116] 256 4 years 3D RV motion 2.75 (1.73 to 4.35)** 
Swift [55] 576 30 months RVESVI (%pred) 1.217 (1.06 to 1.54)**      
RAC 0.76 (0.623 to 0.93)** 
 
RVEF: right ventricular ejection fraction, RVESVI: right ventricular end systolic volume index, LVEDVI: left ventricular 
end diastolic volume index, LVESVI: left ventricular end systolic volume index, SVI: stroke volume index, RAC: relative 
area change, VMI: ventricular mass index, RVIP-LGE: right ventricular insertion point late gadolinium enhancement, 
FWHM: full width half maximum, PTT: pulmonary transit time, RV: right ventricle, * p <0.05, ** p <0.001 
  Advantages Disadvantages 
Chest Radiograph Readily available, low cost Low sensitivity and specific
Echocardiography Readily available, portable, medium cost Operator dependent 
 Diagnostic and prognostic data Poor in lung disease 
Ventilation/Perfusion SPECT Higher sensitivity than CTPA for CTEPH May be non-diagnostic 
 Information regarding lung disease Ionizing radiation 
 
Easy for non-specialists to exclude CTEPH  
Computed Tomography  Readily available, moderate cost Exposure to ionizing radi
 Allows assessment of vascular, cardiac, Inexperienced radiologists 
  mediastinal and lung structures  
 
Quick to perform   
Cardiac MRI Gold standard for ventricular function  
 Non-ionizing 
High cost, post processin
consuming 
  Not always tolerated, co
Abdominal USS Non-ionizing Not specific or sensitive 
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